

1 **Wei Ren Anti-Wart Formula combined with photodynamic**  
2 **therapy for Condyloma acuminata: a double-blind, randomized,**  
3 **parallel-group trial**

4 ShiYan Yang<sup>1§</sup>, Liang Hua<sup>1§</sup>, Dongjie Guo<sup>1</sup>, Yifei Wang<sup>1</sup>, Xuqiang Wei<sup>2\*</sup>, Fulun Li<sup>1\*</sup>

5 <sup>1</sup>Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and  
6 Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai,  
7 China, 200437

8 <sup>2</sup>Acupuncture Anesthesia Clinical Research Institute, Yueyang Hospital of Integrated  
9 Traditional Chinese and Western Medicine, Shanghai University of Traditional  
10 Chinese Medicine, Shanghai, China, 200437

11 **Author contact information**

12 Shi-Yan Yang: [ysya2022@163.com](mailto:ysya2022@163.com)                      Liang Hua: [18916017563@163.com](mailto:18916017563@163.com)

13 Correspondence to Xuqiang Wei: [wxqzdyx123@163.com](mailto:wxqzdyx123@163.com)

14    Phone number: 18916026080

15 Correspondence to Dr Fulun Li: [drlifulun@163.com](mailto:drlifulun@163.com)

16    Phone number: 18918757260

17 \* Correspondence: Xuqiang Wei, Fulun Li

18 § These authors equally contributed to this work.

19 **Word count** (excluding title page, abstract, references, figures, and tables): 4151

20

21 **ABSTRACT**

22 **Introduction:** Condyloma acuminata (CA) is a chronic disease with a high rate of  
23 recurrence which has a detrimental impact on patients' physical and mental health, as  
24 well as their quality of life and socioeconomic advancement. Photodynamic therapy  
25 is a less invasive and selective intervention for CA, but its safety and high price limit  
26 its utilization. Wei Ren Anti-Wart Formula (WRAWF), is a promising Chinese  
27 medicine for CA, however, the evidence of its effectiveness and safety is scarcely.  
28 This trial aimed to evaluate the clinical effectiveness, safety, and recurrence  
29 management of WRAWF combined with photodynamic in the CA patients.

30

31 **Methods and analysis:** A double-blind, randomized, parallel-group trial was  
32 designed. Participants will recruit in the Yue Yang Traditional Chinese Medicine  
33 Hospital, Shanghai University of Traditional Chinese Medicine from May 1, 2024, to  
34 December 31, 2025. The sample size is 148 CA patients (74 in each group), will  
35 randomly divide into the trial and control groups. followed up at weeks 6, 10, and 14  
36 after the 2-week treatment period. The recurrence rate will be set as the primary  
37 outcome. The visual analogue scale (VAS) scores of pain, the rate of infection,  
38 superficial scarring, and the type, severity, and incidence of adverse events will be  
39 carefully documented at 0,1,2,6,10,14 weeks.

40

41 **Ethics and dissemination:** This trial has approved by the Ethics Committee of  
42 Yueyang Hospital of Integrated Traditional Chinese and Western Medicine affiliated

43 to Shanghai University of Traditional Chinese Medicine (No. 2023-023). Meanwhile,  
44 informed consent was provided by all patients conducted in accordance with the  
45 Declaration of Helsinki.

46

47 **Trial registration number:** ChiCTR2300071609; [www.chictr.org.cn](http://www.chictr.org.cn);Registered on  
48 April19, 2023(first version).

49

50 **Key words:** Randomized trial, Condyloma acuminata, photodynamic therapy, Wei  
51 Ren Anti-Wart Formula

52

### 53 **Strengths and limitations of this study**

54 This study evaluate the clinical efficacy, safety, and control of disease recurrence  
55 of CA by sequential treatment of Chinese and Western medicine, to clarify the  
56 advantages of Chinese medicine in the treatment of CA, and for providing a basis for  
57 the formation of a standardized treatment plan.

58 Photodynamic therapy and Chinese medicine for the treatment of CA each have their  
59 characteristics and complementary advantages. To improve the success rate of the  
60 patient's CA treatment and at the same time reduce to some extent the shortcomings of  
61 photodynamic therapy alone such as side effects and easy recurrence.

62

## 63 **BACKGROUND**

64 Condyloma acuminata (CA), also known as anogenital warts, is a sexually  
65 transmitted disease caused by human papillomavirus (HPV) infection that is primarily  
66 a warty, proliferative lesion of the skin and mucous membranes. It typically affects the  
67 skin and mucous membranes of the vaginal, anal, and perianal areas, and yet it can  
68 also affect the inguinal and perineal areas. It has a very high recurrence rate, with a  
69 large sample showing a recurrence rate of (47-163)/100,000 in male and  
70 (23-110)/100,000 in female.[1-4] As a result, CA is prone to recurrence, with the  
71 maximum recurrence rate occurring within 3 months, and then progressively  
72 declining as time goes on. Therefore, it requires long-term, frequent treatment.  
73 Additionally, there is a significant influence on the patient's everyday life and mental  
74 health.

75 Photodynamic therapy (PDT) is a topical application of the photosensitizer  
76 5-aminoketovaleic acid (ALA), followed by topical light treatment with a  
77 semiconductor laser or light emitting diode (LED), usually using red light (630-635  
78 nm). It is indicated for the removal of smaller warts and basal treatment after physical  
79 therapy has removed larger warts. The treatment was performed with a 10%-20%  
80 solution of 5-ALA applied to the lesion, extending to 1 cm around the wart, covering  
81 the subclinical area of infection around the wart as much as possible. For external  
82 genital warts, 3-4 sessions are recommended as a course of treatment for initial cases  
83 and 4-6 sessions for recurrent and recalcitrant cases.[5] The advantage is that it is  
84 non-destructive compared to other therapies such as laser and freezing, can be

85 repeated, and is less likely to cause tissue defects and dysfunction. However, its high  
86 treatment price limits its clinical application.

87 Wei Ren Anti-Wart Formula (WRAWF), a Chinese herbal prescription, is a compound  
88 preparation with eight ingredients (*Clematis chinensis* Osbeck, *Coicis Semen*, *Salvia*  
89 *miltiorrhiza* Bunge, *Astragali Radix*, *Atractylodes macrocephala* Koidz, *Hedyotis*  
90 *Herba*, *Portulaca* and *Curcumae Rhizoma*), achieving clinical efficacy in the external  
91 treatment of CA. It has the advantages of simple use, low treatment cost and few side  
92 effects. External use can act on the wart body.

93 Modern studies have shown that all the extracts of clematichinenside have  
94 significant anti-inflammatory, analgesic, and antispasmodic effects.[6] The  
95 triglyceride component of *Coix lacryma* has anti-tumor effects, and its analgesic and  
96 anti-inflammatory effects have also been confirmed.[7,8] The mechanism of action of  
97 *Salvia miltiorrhiza* may be to suppress the inflammatory response of endothelial cells  
98 by down-regulating the expression of CD40 signals.[9] *Astragalus polysaccharides*  
99 have protective effects against oxidative stress injury and immune damage, and they  
100 promote immune function in traumatic tissues and facilitate wound repair.[10–12]  
101 Curcumin, the main component of *Curcuma longa*, has antitumor and antioxidant  
102 effects, and its ability to effectively scavenge free radicals leads to a reduction in the  
103 possibility of cellular carcinogenesis, and its mechanism of action meets the  
104 requirements of modern medicine needed for anti-photodamage drugs.[13] Therefore,  
105 the combination of the above-mentioned herbs and photodynamic therapy can not  
106 only play a role in reducing the recurrence rate of CA but also synergistically reduce

107 the side effects of treatment and improve the regional immune function with  
108 photodynamic therapy.

109 Therefore, this trial adopts a A double-blind, randomized, parallel-group design to  
110 This trial evaluate the clinical effectiveness, safety, and recurrence management of the  
111 WRAWF combined with photodynamic in the CA patients objectively. The result  
112 will obtain high-level evidence-based medical evidence of Chinese medicine in the  
113 treatment of CA. This protocol will be reported in line with the SPIRIT checklist.

## 114 **METHODS**

### 115 **Design**

116 This is a double-blind, randomized, parallel-group clinical trial. The aim is to  
117 elucidate the clinical efficacy, safety, and recurrence of WRAWF combined with  
118 photodynamic therapy. The results of the study will establish the clinical standard for  
119 sequential treatment of CA with Chinese and Western medicine. The trial protocol  
120 (version 1.0, July 3, 2022) is being written and enrollment in the trial has not yet  
121 begun. Recruitment is expected to begin on May 1, 2024, and end on December 31,  
122 2025.

123 Participants will recruit from the outpatients of Yueyang Hospital of Integrative  
124 Medicine, affiliated with Shanghai University of Traditional Chinese Medicine. A  
125 total of 148 patients will be enrolled in this clinical trial.

126 The study consists of five phases: screening/enrollment, allocation,  
127 treatment/intervention, end of intervention, and follow-up. In the enrollment process,  
128 participants will be recruited via a Condyloma acuminata clinic for physical

129 examination and eligibility assessment. The time between the assessment and the  
130 intervention should not be longer than one week (week 0). If more than a week has  
131 passed since the assessment, assessment of the participant will be repeated before the  
132 intervention. If eligible, the participants will be requested to sign the written informed  
133 consent regarding participation in the trial (procedures, risks, options for dropping  
134 out), the use of laboratory data, and collection, storage, and use of biological  
135 specimens. Details of the informed consent will be explained by study investigators or  
136 medical staff members with adequate training. Once informed consent form is signed  
137 and dated by the participant, a participant identification (PID) number will be  
138 assigned to facilitate participant identification of the study.

139 For the random distribution of WRAWF groups and placebo group, randomisation  
140 will be performed by drawing lots, using the research randomiser program  
141 (<https://www.randomizer.org/>). The allocation sequence will be made by a different  
142 researcher, who will not be involved in the procedures.

143 The participants will be randomly allocated to the WRAWF group or placebo group.  
144 PIDs will be grouped by research randomiser program (<https://www.randomizer.org/>).

145 We will treat the participants in the WRAWF group with WRAWF and PDT, those in  
146 the placebo group with WRAWF placebo and PDT (Fig 1). The participants will  
147 receive systemic therapy as per the judgment of their treating physicians. We will  
148 record all changes in symptoms, prescriptions, relevant scores, and macroscopic  
149 characteristics (based on photographic evidence), as well as any adverse events.

150 The trial protocol was approved by the Ethics Committee of Shanghai Yueyang

151 Hospital of Integrative Medicine and registered in the Clinical Trials Registry.

152 Registration number: 2023-023

153 **Eligibility criteria**

154 Inclusion criteria

155 a) clinical diagnosis of CA, between 18 and 65 years of age; both sexes.

156 b) warts located in the perianal area, distal urethra, and external genitalia.

157 c) who voluntarily participated in this study and signed the informed consent form.

158 Exclusion criteria

159 a) Those who have undergone ALA-PDT treatment within 12 weeks and those who  
160 apply any other treatment that affects the study.

161 b) Those with a combination of other conditions that may affect the evaluation of  
162 efficacy, such as other photo dermatological conditions, combination of severe  
163 localized infections.

164 c) those who have taken phototoxic or photosensitizing drugs within 12 weeks

165 d) clinical and/or pathological evidence of tumor invasion to other organs or tissues.

166 e) Severely immunocompromised individuals.

167 f) Scarred individuals.

168 g) Those with known cutaneous photosensitivity, porphyria, or allergy to ALA, light,  
169 or lidocaine

170 h) Those with severe medical, psychological, and psychiatric illnesses, infectious  
171 diseases, or pregnant or lactating women.

172 i) Any other reason deemed by the investigator to be inappropriate for participation



173 in this study.

174 **Intervention:**

175 **Trial group intervention:**

176 On day 0, day 7, and day 14 of the trial, we gave WRAWF topical application +  
177 Aminoglutaric Acid Hydrochloride topical dispersion + He-Ne laser irradiation once  
178 respectively.

179 Specifically: the test group will get 1 packet of WRAWF granules per dose, put all the  
180 granules of each packet into the same container, pour in about 5 ml of water for  
181 injection, stir until the granules are dissolved, and apply them externally for 30  
182 minutes. Later Aminoketovaleric Acid Hydrochloride topical application is dissolved  
183 in water for injection before use (118mg/bottle add 0.5ml), prepared into a solution  
184 with a concentration of 20%. After cleaning the affected area and keeping it dry, put  
185 the 20% solution of amino glutarate hydrochloride on the cotton ball and cover the  
186 surface of the wart, repeat the solution on the cotton ball every 30 minutes or so, and  
187 keep dressing on the affected area for not less than 3 hours. The entire procedure  
188 should be done in a light-proof environment, and the affected area should be protected  
189 from direct light after the application of the medication. Subsequently, a helium-neon  
190 laser is used, with an output wavelength of 632.8 nm and laser energy of 100-150  
191 J/cm, and the treatment spot completely covers the lesion.

192 **Control group intervention:**

193 Placebo topical application + Aminoketovaleric acid hydrochloride topical  
194 dispersion + He-Ne laser irradiation

195 Specifically: Using placebo topical, placebo herbal granules were composed of a  
196 matrix, color correcting agent, flavoring agent, and a solvent selected according to the  
197 ingredient ratio, made by mixing, drying, crushing, sieving, granulation, and whole  
198 granules; the appearance, odor, and color were the same as the test drug. The  
199 remaining treatment method was the same as the test group.

## 200 **Outcome measures**

201 By employing deterministic, A double-blind, randomized, parallel-group trial, we  
202 aim to furnish precise directives for the secure management of patients diagnosed  
203 with Condyloma acuminata. Data derived from the envisaged outcome metrics will be  
204 amassed for subsequent investigations encompassing larger cohorts. Parameters such  
205 as recruitment and retention rates, the percentage of patients failing to meet eligibility  
206 criteria, and patients' inclination towards random assignment will be computed.  
207 Additionally, assessments will be conducted on compliance levels, qualitative  
208 feedback, and compliance rates. Economical data pertaining to the utilization of  
209 medical resources and health-related quality of life will be gathered and subjected to  
210 comprehensive analysis. Safety outcome measures will be presented in compliance  
211 with the stipulations outlined for a clinical trial designed to scrutinize a  
212 pharmaceutical regimen.

## 213 **Primary outcome:**

214 The main effect indicator was the time to recurrence: the date when a new wart  
215 was found at the treatment site from the first treatment.

## 216 **Secondary outcome:**

217 The secondary effect index is the efficacy evaluation criteria - (1) cured: all warts  
218 were cleared after treatment and no new warts appeared; (2) significantly effective:  
219 the lesion area was reduced by  $\geq 90\%$  after treatment; (3) effective: the lesion area  
220 was reduced by 60% to 89% after treatment; (4) ineffective: the above criteria were  
221 not met. Total effective rate = (cured + effective + effective) / total number of cases  $\times$   
222 100%. The incidence of pain visual analogue scale (VAS) score, infection, and  
223 superficial scar was also recorded during the treatment period, and the patients were  
224 scored for pain, infection, and scar. VAS was used for pain assessment; the Vancouver  
225 Scar Scale (VVS) was used to count and score the incidence and nature of scarring at  
226 the treatment site that appeared late after the patients underwent treatment.(Table 1,  
227 2) At the same time, the type, degree, and incidence of adverse events will be  
228 recorded.

229 The main adverse eactions include local pruritus, redness, swelling, and pain after  
230 treatment; a small number of patients can develop pain at the treatment site at the end  
231 of treatment; clinical treatment adverse reactions are classified into the following four  
232 levels, as shown in Table 3. In the event of an adverse reaction that is not tolerated by  
233 the patient, the follow-up physician can be contacted at any time to ask whether the  
234 drug needs to be discontinued or treated for the adverse reaction. The specific  
235 implementation of such measures is reflected in Table 4.

### 236 **Sample size**

237 According to the literature,[14] the literature recurrence rate is 26.25%.  
238 According to the following formula, we assume that the recurrence rate in the

239 combined treatment group is 8.7%, taking  $\alpha=0.05$  level and test efficacy of 0.8, then  
240  $1-\beta=1-0.2=0.8$ , two-sided test, using two sample rates to compare the sample content  
241 estimation formula. The rate for the test group was  $p_1$  and the rate for the control  
242 group was  $p_2$ , yielding a sample content of 70 cases per group, assuming a 5% loss of  
243 patient follow-up; a total of 148 patients needed to be observed, 74 cases per group.

$$n_1 = n_2 = \frac{p_1 \times (1 - p_1) + p_2(1 - p_2)}{(p_2 - p_1)^2} \times (u_{\alpha/2} + u_{\beta})^2$$

#### 244 **Randomization and allocation**

245 The trial was completely randomized and was conducted by the Data  
246 Management Center of Jiangsu Famaxon Medical Technology Co. The system will  
247 give a subject identification number, i.e., subject ID, as a unique identification number  
248 after enrollment. After obtaining the subject ID, the subjects were grouped by logging  
249 into the randomization center website, and the corresponding randomization number  
250 was obtained to enter the group.

#### 251 **Treatment cycles**

252 The study period was 15 weeks in total: photodynamic therapy (3 weeks) +  
253 follow-up period (12 weeks).

#### 254 **Test drugs and blinding**

255 The study drug and its placebo were manufactured, packaged, and provided by  
256 Sichuan Neo-green Pharmaceutical Technology Development Co., Ltd. The study  
257 drug randomization code was the unique identification code for the subjects. A  
258 double-blind design was used, and the randomization code table was created by the  
259 research randomiser program (<https://www.randomizer.org/>). Each participant's

260 corresponding PID will be given a unique random number and a corresponding drug  
261 packet or placebo packet with the same appearance, odor, and color. The project team  
262 will designate separate dispensers who will not be involved in other parts of that  
263 clinical trial. The monitors and outcome evaluators had to be blinded from the  
264 beginning to the end.

265 Unblinding regulations: This study provides for one unblinding. The unblinding is  
266 done after the blinded verification data is locked, and the staff member who keeps the  
267 blinded base will give it to the statistician for statistical analysis.

268 Emergency unblinding: When a serious adverse event occurs, or when a patient needs  
269 to be resuscitated and other circumstances necessitate knowledge of the drug used by  
270 the patient, the person in charge of the central trial will decide to unblind the patient  
271 in an emergency and open the corresponding emergency letter. Once the emergency  
272 letter with the corresponding number is opened, the case will be treated as a dislodged  
273 case.

#### 274 **Drug combination**

275 Any medications taken at study entry and during the three months prior to study,  
276 entry must be recorded on the Case Report Form (CRF). All medications used during  
277 the study are considered to be combined medications and must also be recorded on the  
278 CRF form. In particular, all permitted or unpermitted use of any measures for the  
279 treatment of psoriasis should be recorded. Combination medications should be  
280 recorded by type (trade name), dosage, indication, and duration of administration on  
281 the appropriate CRF page. The investigator decides whether the patient withdraws

282 from the study.

283 I. Permissible combined treatments: certain drugs/other treatments that must be  
284 taken by patients with comorbid diseases or new comorbid diseases during treatment  
285 will be permissible, provided that the name of the drug (or other treatment names),  
286 dosage, number and duration of use, etc., are recorded in the study medical record for  
287 analysis and reporting at the time of summary.

288 II. Prohibited combined treatments: other internal medications, topical preparations,  
289 physiotherapy, etc. to treat the disease, including vitamin D3 derivatives, other herbal  
290 preparations, etc.

### 291 **Statistical analysis**

292 Data management was performed using the data management platform designed  
293 by the Data Management Center of Jiangsu Famaxon Medical Technology Co., Ltd,  
294 which included data management, blinded audit, and data export were performed in  
295 this platform for data entry. The analyses will be performed using SAS statistical  
296 software and will include the actual number of subjects enrolled in both groups,  
297 disenrollment and exclusion cases, demographic and other baseline characteristics,  
298 adherence, efficacy analysis, and safety analysis.

299 Statistical analysis was performed using descriptive statistical analysis and  
300 comparative analysis between the two groups. Qualitative indicators were described  
301 by frequency tables, percentages, or composition ratios; quantitative indicators were  
302 described by means, standard deviations, or medians, lower quartiles (Q1), upper  
303 quartiles (Q3), minimums, and maximums. Qualitative data were tested by the

304 chi-square test, Fisher's exact probability method, Wilcoxon rank sum test, and CMH  
305 test. Quantitative data conformed to a normal distribution by t-test (chi-square test  
306 between groups, with 0.05 as the test level, and Satterthwaite's method was used for  
307 corrected t-test when the variance was not equal), and Wilcoxon rank sum test and  
308 Wilcoxon signed rank sum test were used for non-normal distribution. Hypothesis  
309 testing was uniformly performed using a two-sided test, giving the test statistic and its  
310 corresponding P value, with  $P \leq 0.05$  as statistically significant and  $P \leq 0.01$  as highly  
311 statistically significant.

## 312 **Adverse events**

313 I. Recording of adverse reactions or adverse events: ① The investigator should  
314 explain to the patients and ask them to respond truthfully to the changes in their  
315 condition after medication and avoid induced questions; ② While observing the  
316 efficacy, pay close attention to the observation of adverse reactions or unanticipated  
317 toxic side effects, analyze the causes, make judgments, and follow up the observation  
318 and records, and count the incidence of adverse reactions; ③ For the adverse  
319 reactions occurring during the study period, the symptoms, the degree, time of  
320 appearance, duration, treatment measures, and passage should be recorded on the case  
321 report form to evaluate its relevance to the test drug, and be recorded in detail by the  
322 investigator, signed and dated.

323 II. Reporting of adverse reactions or adverse events: ① When adverse reactions are  
324 found, the observing physician may decide whether to discontinue observation  
325 according to the condition, and cases of discontinuation due to adverse reactions

326 should be followed up and investigated, with detailed records of treatment and results;  
327 ② If serious adverse events occur in the trial, the unit undertaking the clinical study  
328 must take immediate measures to protect the safety of the subjects and promptly  
329 inform the participating research units, and Ensure that all legal and regulatory  
330 requirements for reporting procedures are met.

### 331 **Data management and monitoring**

332 The data management of this project was entrusted to the Data Management  
333 Center of Jiangsu Famaxon Medical Technology Co. This project uses the clinical  
334 data management platform, and the data manager constructs e-CRF according to the  
335 study protocol and case report form.

#### 336 I. Data record

337 In view of the situation that most of the outpatient medical records in China's  
338 hospitals are brought by the patients themselves, to keep the first-hand data of the  
339 clinical trial intact, we design this trial-specific: "study medical record". The study  
340 medical record is the source document of the clinical trial subjects, which should be  
341 kept in the hospital. The study medical record is the medical record of the outpatient  
342 subjects, and together with the inpatient medical record, it forms the medical record of  
343 the subjects.

#### 344 II. Study case record requirements

345 The investigator must write the study case record at the same time as the subject  
346 is seen and treated to ensure that data are recorded in a timely, complete, accurate, and  
347 truthful manner.



348 Any substantiated corrections made to the study medical record may only be crossed  
349 out, with the corrected data noted next to it, signed and dated by the investigator, and  
350 not erased or overwritten on the original record.

351 Original lab sheets for outpatient subjects are affixed to the study medical record and  
352 original lab sheets for inpatient subjects are affixed to the inpatient medical record.

353 The results of laboratory tests for both outpatient and inpatient subjects must be  
354 completed in the "Physical and Chemical Findings Report Form" in the study medical  
355 record.

### 356 III. Review of medical records

357 After each subject's observation session, the investigator should submit the "study  
358 medical record", "informed consent" and "patient medication record card" to the  
359 principal investigator of the unit within 3 working days. Within one week, they should  
360 be submitted to the project leader for review and deposited in the institutional data  
361 archive, and any problems found should be dealt with and recorded on time.

### 362 IV. Data Entry and Modification

363 Data entry and management are the responsibility of the clinical coordinator and  
364 data manager, respectively. Each study center will be given a separate username and  
365 password before the start of the project, and a designated person from the study center  
366 will enter the raw data into the EDC via a secure network. Study center personnel will  
367 be allowed to make changes to the entered data during the entry process. The  
368 supervisor confirms that all data in the EDC is consistent with the original record. If  
369 there are errors or omissions, a challenge form is sent to the research center personnel

370 to request changes to the data in the EDC.

371 The data management department reviews the data recorded in the EDC by standard  
372 operating procedures. For queries in the data, the data manager will send a query to  
373 the research center personnel in the form of a query form, requesting the designated  
374 personnel of the research center to respond to the query and make the necessary  
375 changes to the data. All data changes and related operations shall be recorded with a  
376 trace.

#### 377 V. Data Monitoring

378 The number of monitors and the number of visits must meet the quality control  
379 requirements of the clinical trial. Supervisors shall review each study medical record  
380 and fill in the "Supervisor Review Page" one by one.

381 During the monitoring process, they should check the completeness of the case  
382 records and the accuracy of the case report form, verify the trial data, check the  
383 compliance with the trial protocol and clinical trial management specifications,  
384 understand the progress of the enrolled subjects, and ensure the storage, distribution,  
385 and use of the trial products. The investigator and related personnel should assist the  
386 monitor during his or her visit and arrange an appropriate workspace for him or her.

#### 387 VI. Database locking

388 After a blind audit and confirmation that the database created is correct, a data  
389 management audit report is written by the data manager, and the data is locked by the  
390 principal investigator, sponsor, and statistical analyst. No further changes will be  
391 made to the locked data files.

392 **DISCUSSION**

393 CA is a proliferative genital perianal lesion caused by infection with the human  
394 papilloma (HPV) virus. Its incidence is three times higher than that of genital herpes,  
395 and most patients are young people aged 18-35.[15,16] Thev infection of warts not  
396 only has physical and psychological effects but the pathogen HPV is also  
397 carcinogenic in addition to causing warty growths.[17] Evidence suggests that HPV  
398 infection is closely associated with the development of cervical cancer.[18]

399 The typical CA is a small, reddish papule that gradually increases in size and has an  
400 uneven surface, and then further proliferates into a wart-like protrusion and spreads to  
401 the periphery. The most important thing is that you can feel the pain of intercourse,  
402 and occasionally the infection may be oozing, ulcerated, or bleeding.

403 The principles of CA treatment are to remove as many warts as possible and to reduce  
404 recurrence. Although there are several treatments for warts, there is a risk of  
405 recurrence with any of them.[19] There is no definitive answer as to which method is  
406 the best for treating warts.

407 In Traditional Chinese Medicine (TCM), it is mainly contact with evil toxins, and  
408 damp heat, which is caused by the accumulation of damp heat toxins on the pudendal  
409 skin. The TCM syndrome types of this disease are mainly divided into two types:  
410 damp-heat toxin accumulation syndrome and dampness and toxicity gather in the  
411 lower, while CA is mainly localized, so external treatment is often used for treatment.

412 The effect of drugs can penetrate the skin directly to the affected part.[20] In China,  
413 the compound external preparation mainly composed of Brucea javanica, Sophora

414 flavescens, Honeysuckle, Folium Isatidis, diffusa diffusa, honeydew, fructus cnidii,  
415 and other traditional Chinese medicines has been used for many years. Studies have  
416 shown that it can inhibit and kill HPV through cytotoxicity.[21,22] There are also  
417 external preparations of cantharidin, which are effective in the removal of the wart  
418 body and the prevention of recurrence. However, due to the difficulty of  
419 standardization and the limitations of the research methods adopted, there is a lack of  
420 relevant high-quality evidence-based medical evidence.

421 In this trial, we will use granular formulations to minimize bias associated with the  
422 use of herbs from different geographic regions, different species, and preserved under  
423 different storage conditions. In this study, it refers to clarify the superior aspects of  
424 Chinese medicine in the treatment of CA and to obtain high-level evidence-based  
425 medical evidence to provide a basis for the formation of standardized treatment  
426 protocols.

#### 427 **Ethics and dissemination**

428 This trial has been ethically approved by the Ethics Committee of Shanghai  
429 Yueyang Hospital of Integrative Medicine (approval number:2023-023) All  
430 participants will be enrolled only after signing the informed consent form. No clinical  
431 data or biological samples will be collected from those who do not participate. The  
432 trial will comply with national laws, clinical practice guidelines, and the Declaration  
433 of Helsinki as revised in 2013. Results will be published through meeting reports and  
434 publicly available documents.

#### 435 **Trial status**

436 The trial phase begins in JAN 2024 at Shanghai Yueyang Hospital for Integrative  
437 Medicine and is currently being prepared for patient recruitment.

438 **Contributors:**

439 **SY** drafted the manuscript. **LH** participated in the design of the study, and **YFW**  
440 coordinated the study. **WXQ** will generate the allocation sequence, **DJG** will enrol  
441 participants, and **XQW** and **FLL** will assign participants to interventions. All authors  
442 read and approved the final manuscript.

443 **Funding statement:** Shanghai Municipal Health Commission Health Industry  
444 Clinical Research Specialization(20224Y0056,20214Y0175),Shanghai Sailing  
445 Program(no.20YF1450500)

446 **Competing interests statement:** None declared.

447 **Patient consent Patient:** recruitment has not started.

448 **Ethics approval:** Institutional Ethics Committee of Shanghai Yueyang Integrated  
449 Medicine Hospital.

450

451 **Figures legends**

452 **Figure 1.Flow diagram showing progress through the study**

453


---

454 **Tables**

455 **Tables1. Visual analogue scale (VAS)**


456 Visual analogue scale

457 No pain Worst pain imaginable



459 Numerical rating scale

460 No pain Worst imaginable pain



462

463 Verbal rating scale

464 0 No pain

465 1 Mild pain

466 2 Moderate pain

467 3 Severe pain

468

469 **Tables2. VANCOUVER SCAR SCORING(VVS)**

---

**VANCOUVER SCAR SCORING**

---

**Pigmentation**

0 Normal

1 Hypopigmentation or hyperpigmentation not exceeding 5% of the whole

2 Hyperpigmentation ranging between 5% and 30% of the whole

3 Hyperpigmentation not G30% of the whole

**Vascularity**

0 Normal

1 Red

2 Slightly dark red

3 Much darker red

**Pliability**

0 Normal

1 Supple

2 Yielding

3 Firm

4 Banding

5 Contracture

**Height**

0 Normal

1 Elevation of 0Y1 mm

2 Elevation of 1Y2 mm

3 Elevation of 2Y4 mm

4 Elevation of Q4 mm

**Length**

The length of the scar was measured with a medical ruler.

---

470

471 **Tables3. Adverse reaction level evaluation table**

**Adverse reaction level evaluation table**

Level 1 Safe, no adverse reactions

Level 2 safer, minor adverse reactions, but does not affect treatment

Level 3 There are certain safety issues, there is a certain degree of adverse reactions, but after treatment can continue treatment

Grade 4 Adverse reactions occur, resulting in the inability to continue treatment

472

473

474 **Table 4. Schedule for enrollment, intervention, and assessment**

Activity	Phase	Screening/ Enrolment	Treatment/Intervention			Follow-up		
	Time points	0week	0week	1week	2week	6week	10week	14week
Screening/ Enrolment	Eligibility screening	●						
	Obtaining informed consent	●						
	Demographic characteristics	●						
	Medical history taking	●						
	Enrolment	●						
	Random allocation	●						
	Skin lesion photography	●		●	●	●	●	●
Treatment/Intervention	WRAWF + Photodynamic		●	●	●			
	Placebo + Photodynamic		●	●	●			
Outcome assessment	Recurrence					●	●	●
	Efficacy evaluation		●	●	●	●	●	●
Safety assessment	VAS score		●	●	●	●	●	●
	Infection		●	●	●	●	●	●
	Superficial scarring		●	●	●	●	●	●

475 WRAWF, Wei Ren Anti-Wart Formula ; VAS, visual analogue scale

476



---

477 **References**

- 478 1 Sarika Desai, Sally Wetten, Sarah C. Woodhall, *et al.* Genital warts and cost of care in England.  
479 *Sex Transm Infect.* 2011;87:464–8.
- 480 2 J. Monsonégo, J.-G. Breugelmans, S. Bouée, *et al.* [Anogenital warts incidence, medical  
481 management and costs in women consulting gynaecologists in France]. *Gynecol Obstet Fertil.*  
482 2007;35:107–13.
- 483 3 Peter Hillemanns, J. Gabrielle Breugelmans, Friederike Giesecking, *et al.* Estimation of the  
484 incidence of genital warts and the cost of illness in Germany: a cross-sectional study. *BMC*  
485 *Infect Dis.* 2008;8:76.
- 486 4 Xavier Castellsagué, Catherine Cohet, Luis M. Puig-Tintoré, *et al.* Epidemiology and cost of  
487 treatment of genital warts in Spain. *Eur J Public Health.* 2009;19:106–10.
- 488 5 Peiyao Zhu, Rui-Qun Qi, Yang Yang, *et al.* Clinical guideline for the diagnosis and treatment of  
489 cutaneous warts (2022). *J Evid Based Med.* 2022;15:284–301.
- 490 6 Wang Han, Ying Xiong, Yunman Li, *et al.* Anti-arthritic effects of clematichinenoside (AR-6) on  
491 PI3K/Akt signaling pathway and TNF- $\alpha$  associated with collagen-induced arthritis. *Pharm Biol.*  
492 2013;51:13–22.
- 493 7 Yingling Sui, Deping Xu. Isolation and identification of anti-inflammatory and analgesic  
494 polysaccharides from Coix seed (Coix lacryma-jobi L.var. Ma-yuen (Roman.) Stapf). *Nat Prod*  
495 *Res.* 2022;1–10.
- 496 8 Yun Lu, Bing-Yuan Zhang, Zhuo-Xia Jia, *et al.* Hepatocellular carcinoma HepG2 cell apoptosis  
497 and caspase-8 and Bcl-2 expression induced by injectable seed extract of Coix lacryma-jobi.  
498 *Hepatobiliary Pancreat Dis Int.* 2011;10:303–7.
- 499 9 Guang-De Yang, Hui Zhang, Rong Lin, *et al.* Down-regulation of CD40 gene expression and  
500 inhibition of apoptosis with Danshensu in endothelial cells. *Basic Clin Pharmacol Toxicol.*  
501 2009;104:87–92.
- 502 10 Ma L. Astragalus Polysaccharides Promote Wound Healing in Diabetic Rats by Upregulating  
503 PETN and Inhibiting the mTOR Pathway. *Comput Math Methods Med.* 2022;2022:3459102.
- 504 11 Yue Y, Liu X, Pang L, *et al.* Astragalus Polysaccharides/PVA Nanofiber Membranes Containing  
505 Astragaloside IV-Loaded Liposomes and Their Potential Use for Wound Healing. *Evid Based*  
506 *Complement Alternat Med.* 2022;2022:9716271.
- 507 12 Hamid M, Liu D, Abdulrahim Y, *et al.* Amelioration of CCl(4)-induced liver injury in rats by  
508 selenizing Astragalus polysaccharides: Role of proinflammatory cytokines, oxidative stress  
509 and hepatic stellate cells. *Res Vet Sci.* 2017;114:202–11.
- 510 13 Abadi Aj, Mirzaei S, Mahabady Mk, *et al.* Curcumin and its derivatives in cancer therapy:  
511 Potentiating antitumor activity of cisplatin and reducing side effects. *Phytotherapy research :*

- 
- 512 PTR. 2022;36. doi: 10.1002/ptr.7305
- 513 14 Zhang L-L, Cai H-G, Ji Z-Zhou J, Zhang J, Yang S-J. Observation of clinical effects and analysis  
514 of adverse reactions of carbon dioxide laser combined with photodynamic therapy for vulvar  
515 acromegaly. [J] *Journal of Nantong University (Medical Edition)*. 2022;42(01):59-61.
- 516 15 Dareng EO, Adebamowo SN, Famooto A, *et al*. Prevalence and incidence of genital warts and  
517 cervical Human Papillomavirus infections in Nigerian women. *BMC Infect Dis*. 2019;19:27.
- 518 16 Patel H, Wagner M, Singhal P, *et al*. Systematic review of the incidence and prevalence of  
519 genital warts. *BMC Infect Dis*. 2013;13:39.
- 520 17 Okunade KS. Human papillomavirus and cervical cancer. *J Obstet Gynaecol*. 2020;40:602–8.
- 521 18 Rymysa T, Ribeiro Ea, de Carvalho Lfdces, *et al*. Human papillomavirus detection using PCR  
522 and ATR-FTIR for cervical cancer screening. *Spectrochimica acta Part A, Molecular and*  
523 *biomolecular spectroscopy*. 2018;196. doi: 10.1016/j.saa.2018.02.004
- 524 19 Prayogo SA, Andrew H, Cong S, *et al*. Photodynamic therapy in the treatment of condyloma  
525 acuminata: A systematic review of clinical trials. *Int J STD AIDS*. 2023;34:76–86.
- 526 20 Lei Shi, Hongwei Wang, Kun Chen, *et al*. Chinese guidelines on the clinical application of  
527 5-aminolevulinic acid-based photodynamic therapy in dermatology (2021 edition).  
528 *Photodiagnosis Photodyn Ther*. 2021;35:102340.
- 529 21 Chen X, Hu X, Liu L, *et al*. Extracts derived from a traditional Chinese herbal formula triggers  
530 necroptosis in ectocervical Ect1/E6E7 cells through activation of RIP1 kinase. *Journal of*  
531 *ethnopharmacology*. 2019;239. doi: 10.1016/j.jep.2019.111922
- 532 22 Ling Ye, Jian-Fu Zhao, Yi-Ming Wang, *et al*. Brucea javanica oil emulsion suppresses tumor  
533 growth in human cervical cancer cells through inhibition of the E6 oncogene and induction of  
534 apoptosis. *Translational cancer research*. 2020;9. doi: 10.21037/tcr.2019.12.62
- 535